Bavdegalutamide

Bavdegalutamide
Clinical data
Other names	ARV-110
Identifiers
	IUPAC name N-[4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-[[4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindol-5-yl]piperazin-1-yl]methyl]piperidin-1-yl]pyridazine-3-carboxamide;
PubChem CID	134414307;
Chemical and physical data
Formula	C41H43ClFN9O6
Molar mass	812.30 g·mol−1

Bavdegalutamide is an experimental androgen receptor degrader that works via proteolysis targeting chimera.^[1] It is being developed to treat metastatic castration-resistant prostate cancer.^[2]

References

^ PubChem. "Bavdegalutamide". pubchem.ncbi.nlm.nih.gov. Retrieved 2024-10-31.
^ Shore, Neal D.; Shen, John; Devitt, Michael Edward; Lu, Haolan; Alicea, Jeanette; Parameswaran, Janaki; Chirnomas, Deborah; Gao, Xin; McKean, Meredith (2022-06-01). "Phase 1b study of bavdegalutamide, an androgen receptor PROTACdegrader, combined with abiraterone in patients with metastatic prostate cancer". Journal of Clinical Oncology. 40 (16_suppl): TPS5106–TPS5106. doi:10.1200/JCO.2022.40.16_suppl.TPS5106. ISSN 0732-183X.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.